Conference Coverage

Riociguat benefits persist in pulmonary hypertension

Publish date: November 27, 2013

 

AT CHEST 2013

CHEST-2 and PATENT-2 are supported by Bayer Healthcare, maker of riociguat. Dr. Simonneau and Dr. Lewis reported financial relationships with several drug companies including Bayer.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Macitentan cuts morbidity, mortality in PAH
MDedge Rheumatology
Study sheds light on exacerbation risks with RA lung disease
MDedge Rheumatology
Limited data support multiple myositis treatment options
MDedge Rheumatology
Flu outlook 2013-2014: Don’t hesitate. Vaccinate!
MDedge Rheumatology
Autoantibodies play role in myositis classification, treatment
MDedge Rheumatology
Novel oral vasodilator approved to treat pulmonary hypertension
MDedge Rheumatology
Macitentan approved for pulmonary arterial hypertension
MDedge Rheumatology
Treatment options expand for pulmonary arterial hypertension in scleroderma
MDedge Rheumatology
Smoking has damaging impact in ankylosing spondylitis
MDedge Rheumatology
Failure to diagnose
MDedge Rheumatology